BLAINJECTIONINJECTABLE
Approved
Nov 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
TRUXIMA (rituximab-abbs) by Celltrion is cd20-directed antibody interactions [moa]. Approved for cd20-directed cytolytic antibody [epc]. First approved in 2018.
Drug data last refreshed 21h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRUXIMA is a rituximab biosimilar (rituximab-abbs) developed by Celltrion and approved in 2018 as a monoclonal antibody targeting CD20-positive B cells. It is used to treat CD20-positive B-cell malignancies and autoimmune conditions by triggering cytolytic destruction of target cells. The drug is administered via intravenous injection.
$0.015BPart D
PeakStable
TRUXIMA is at peak maturity in a crowded CD20 biosimilar market; career growth will depend on commercial efficiency and differentiation rather than organic expansion.
Mechanism of Action
CD20-directed Antibody Interactions
Pharmacologic Class:
CD20-directed Cytolytic Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)
Started Jul 2022
60 enrolled
Lymphoma, Large B-Cell, Diffuse (DLBCL)
Career Relevance
TRUXIMA offers limited career growth potential given its peak-stage, low-spending profile ($15M) in a highly competitive biosimilar market with minimal linked job openings. Career value is concentrated in commercial efficiency, pricing strategy, and market access roles rather than innovation or clinical development.
Brand Manager
Worked on TRUXIMA at Celltrion? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.